A Variant in PNPLA3 Associated With Fibrosis Progression but not Hepatocellular Carcinoma in Patients With Hepatitis C Virus Infection

Clinical Gastroenterology and Hepatology

Volumn 14, Issue 2, 2016, Pages 295-300

  Ali, Muhammad ^a   Yopp, Adam ^a   Gopal, Purva ^a   Beg, Muhammad S ^a   Zhu, Hao ^a   Lee, William ^a   Singal, Amit G ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Adiponutrin; Cirrhosis; HALT C cohort; Hepatitis C; Liver cancer; Viral hepatitis

Indexed keywords

PEGINTERFERON; ADIPONUTRIN, HUMAN; MEMBRANE PROTEIN; TRIACYLGLYCEROL LIPASE;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; OBESITY; PNPLA3 GENE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; CARCINOMA, HEPATOCELLULAR; CASE CONTROL STUDY; CHRONIC HEPATITIS C; COMPLICATION; FIBROSIS; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; FEMALE; FIBROSIS; GENETIC PREDISPOSITION TO DISEASE; HEPATITIS C, CHRONIC; HUMANS; LIPASE; MALE; MEMBRANE PROTEINS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; YOUNG ADULT;

EID: 84958941381     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2015.08.018     Document Type: Article

References (28)

1. El-Serag H.B. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012, 142:1264-1273 e1261.
2. El-Serag H.B., Kramer J., Duan Z., et al. Racial differences in the progression to cirrhosis and hepatocellular carcinoma in HCV-infected veterans. Am J Gastroenterol 2014, 109:1427-1435.
3. El-Serag H.B., Lau M., Eschbach K., et al. Epidemiology of hepatocellular carcinoma in Hispanics in the United States. Arch Intern Med 2007, 167:1983-1989.
4. Fattovich G., Stroffolini T., Zagni I., et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004, 127:S35-S50.
5. Singal A.G., Mukherjee A., Joseph Elmunzer B., et al. Machine learning algorithms outperform conventional regression models in predicting development of hepatocellular carcinoma. Am J Gastroenterol 2013, 108:1723-1730.
6. Hassan M.M., Spitz M.R., Thomas M.B., et al. The association of family history of liver cancer with hepatocellular carcinoma: a case-control study in the United States. J Hepatol 2009, 50:334-341.
7. Sookoian S., Pirola C.J. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011, 53:1883-1894.
8. Singal A.G., Manjunath H., Yopp A.C., et al. The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis. Am J Gastroenterol 2014, 109:325-334.
9. Trepo E., Nahon P., Bontempi G., et al. Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: evidence from a meta-analysis of individual participant data. Hepatology 2014, 59:2170-2177.
10. Lee W.M., Dienstag J.L., Lindsay K.L., et al. Evolution of the HALT-C trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials 2004, 25:472-492.
11. Singal A.G., Nehra M., Adams-Huet B., et al. Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail?. Am J Gastroenterol 2013, 108:425-432.
12. Lok A.S., Seeff L.B., Morgan T.R., et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009, 136:138-148.
13. Dunn W., Zeng Z., O'Neil M., et al. The interaction of rs738409, obesity, and alcohol: a population-based autopsy study. Am J Gastroenterol 2012, 107:1668-1674.
14. Trepo E., Gustot T., Degre D., et al. Common polymorphism in the PNPLA3/adiponutrin gene confers higher risk of cirrhosis and liver damage in alcoholic liver disease. J Hepatol 2011, 55:906-912.
15. Patin E., Kutalik Z., Guergnon J., et al. Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. Gastroenterology 2012, 143:1244-1252. e1242.
16. Rembeck K., Maglio C., Lagging M., et al. PNPLA 3 I148M genetic variant associates with insulin resistance and baseline viral load in HCV genotype 2 but not in genotype 3 infection. BMC Med Genet 2012, 13:82-88.
17. Valenti L., Fargion S. Patatin-like phospholipase domain containing-3 Ile148Met and fibrosis progression after liver transplantation. Hepatology 2011, 54:1484.
18. Trepo E., Pradat P., Potthoff A., et al. Impact of PNPLA3 (RS738409 C>g) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. J Hepatol 2011, 54:S55.
19. Huang Y., Cohen J.C., Hobbs H.H. Expression and characterization of a PNPLA3 protein isoform (I148M) associated with nonalcoholic fatty liver disease. J Biol Chem 2011, 286:37085-37093.
20. Valenti L., Dongiovanni P., Ginanni, et al. PNPLA3 I148M variant and hepatocellular carcinoma: a common genetic variant for a rare disease. Dig Liver Dis 2013, 45:619-624.
21. Ampuero J., Rojas L., Calle R., et al. I148M PNPLA3 variant promotes steatosis according to viral and IL28B genotype but does not affect sustained viral response in patients with hepatitis C. J Hepatol 2013, 58:S180.
22. Muller T., Buch S., Berg T., et al. Distinct, alcohol-modulated effects of PNPLA3 genotype on progression of chronic hepatitis C. J Hepatol 2011, 55:732-733.
23. Falleti E., Fabris C., Cmet S., et al. PNPLA3 rs738409C/G polymorphism in cirrhosis: relationship with the aetiology of liver disease and hepatocellular carcinoma occurrence. Liver Int 2011, 31:1137-1143.
24. Guyot E., Sutton A., Rufat P., et al. PNPLA3 rs738409, hepatocellular carcinoma occurrence and risk model prediction in patients with cirrhosis. J Hepatol 2013, 58:312-318.
25. Hamza S., Petit J.M., Masson D., et al. Pnpla 3 RS738409 GG homozygote status is associated with increased risk of hepatocellular carcinoma in cirrhotic patients. J Hepatol 2012, 56:S281-S282.
26. Lawitz E., Poordad F.F., Pang P.S., et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2014, 383:515-523.
27. Younossi Z.M., Stepanova M., Henry L., et al. Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2014, 12:1349-1359. e1313.
28. Singal A.G., Volk M.L., Jensen D., et al. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 2010, 8:280-288. 288 e281.